Tech Company Financing Transactions
Cagent Vascular Funding Round
Cagent Vascular closed a $41 million Series D venture capital round on 5/19/2026. Investors included U.S. Venture Partners and private investors.
Transaction Overview
Company Name
Announced On
5/19/2026
Transaction Type
Venture Equity
Amount
$41,000,000
Round
Series D
Investors
U.S. Venture Partners (Lead Investor) (Casey Tansey)
Proceeds Purpose
The round builds on a commercial foundation already established; Cagent Vascular's Serranator® portfolio is sold nationally across most major U.S. markets, and select major international markets.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
150 Strafford Ave. 315
Wayne, PA 19087
USA
Wayne, PA 19087
USA
Phone
Website
Email Address
Overview
Cagent Vascular is leading the way for next generation technology for vessel dilatation. It is the second cardiovascular company formed by co-founders Carol Burns, President & CEO, Peter Schneider, MD, Vascular Surgeon, Chief Medical Officer and Robert Giasolli, VP of Research and Development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Carol Burns
Chief Medical Officer
Peter Schneider
Chief Operating Officer
Peter Johansson
Chief Technical Officer
Robert Giasolli
VP - Finance
Aaron Green
Browse more venture capital transactions:
Prev: 5/19/2026: Tomoland venture capital transaction
Next: 5/19/2026: Anaergia Technologies venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs